The commotion over mega-blockbuster drugs Ozempic and Wegovy (Semaglutide) has made tremendous headlines in 2023. Celebrities, athletes, and regular people have been turning to these drugs to lose weight. These medicines have helped to turn Danish drugmaker Novo Nordisk into a $400B company! Novo Nordisk's share price has more than quadrupled in the past five years, making it Europe's most valuable company by market cap. However, studies have found that semaglutide leads to a significant decrease in fat-free mass (aka muscle mass) compared with a placebo. Furthermore, because this drug is focused on reducing appetite, if patients go off the drug their food consumption increases and they readily regain weight. One little-known biotech company has a potential treatment that could blow Ozempic and Wegovy out of the water!
It's called a next-generation CB1 inhibitor and it uses a different mechanism to achieve important, long-lasting impacts on weight and related conditions such as kidney diseases! Biotech observers believe there are numerous opportunities for differentiated and improved therapeutic outcomes in the burgeoning weight loss and cardiometabolic space. Could there be potential here for this company to play a strong role in this emerging future? Big pharma is seeing the appeal of CB1 receptors: Recent acquisitions highlight interest in the ECS: Jazz Pharmaceuticals/GW Pharmaceuticals/epilepsy - $7.2B (2021); Horizon/Zynerba/Fragile X drug – up to $200M (2023); in 2023, the largest seller of drugs used for weight loss, Novo Nordisk, acquired Inversago Pharma and its peripheral CB1-inhibiting drug (with only Phase 1 data) for up to $1.075 billion.
This message is a PAID ADVERTISEMENT for Skye Bioscience, Inc. (OTCQB: SKYE) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1,900. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Skye Bioscience, Inc. (OTCQB: SKYE) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Skye Bioscience, Inc. (OTCQB: SKYE) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and Skye Bioscience, Inc. (OTCQB: SKYE).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com
Post a Comment
Post a Comment